Creating new treatments for stimulant use disorder
Official title: Development of sigma receptor/DAT dual-targeting compounds to treat stimulant use disorder
Funded at Sparian Biosciences, INC. · NIH-10897743 · Data updated 2026-11-12
This study is testing a new medication called SBS-518 that aims to help people struggling with stimulant use disorder, like those using methamphetamine or cocaine, by reducing their cravings without giving them a high, and there may be chances for patients to join early trials as the research moves forward.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sparian Biosciences, INC. NIH-funded |
| Lab location | 1 site (New York City, United States) |
| Project start | August 15, 2023 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $4,017,447 |
| NIH project number | 5UG3DA058553-02 |
| Project ID | NIH-10897743 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with stimulant use disorder who are seeking treatment options.
✕Less likely to help
Patients who are not struggling with stimulant use disorder or those who have not responded to previous stimulant treatments may not benefit from this research.
What this research studies
This research focuses on developing a new medication, SBS-518, aimed at treating stimulant use disorder (StUD), which affects millions of people in the U.S. The approach involves targeting specific brain receptors to reduce the urge to use stimulants like methamphetamine and cocaine without causing rewarding effects. The research will include optimizing the lead compound and conducting necessary safety studies before moving towards clinical trials. Patients may have the opportunity to participate in early-stage trials as the treatment progresses.
Why it matters
Potential benefit: If successful, this research could provide a much-needed pharmacotherapy for individuals struggling with stimulant use disorder.
How similar studies have gone: While stimulant use disorder treatment is an emerging field, this approach is novel as there are currently no FDA-approved medications specifically for StUD.
Where this research is happening
-
Sparian Biosciences, INC.
New York City, United States Active
Researchers
- Principal investigator: Reich, Jeffrey — Sparian Biosciences, INC.
- Study coordinator: Reich, Jeffrey
Related research
Other NIH-funded projects on the same topics.
-
First-in-class, non-opioid pain medicine (SBS-147) for acute and chronic pain
A new non-opioid pill called SBS-147 may help adults manage acute and chronic pain with less risk of dependence or overdose.
-
SBS-226: a new medication that activates one opioid receptor and blocks another to treat opioid addiction
This project develops SBS-226, a potential medicine designed to reduce opioid cravings and withdrawal by activating the mu-opioid receptor while blocking the delta-opioid receptor for people with opioid use disorder.
-
Developing a new treatment for opioid use disorder
This study is testing a new medication called SBS-226 to help people with opioid use disorder by providing pain relief without the same risk of addiction that comes with regular opioids.
-
A new class of safer pain relievers
This study is testing a new type of pain relief medication called MP1000, which aims to help people manage pain without the risks of addiction that come with traditional opioids.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.